inflammatory diseases

Moon Lake
Biotech

MoonLake stock sinks as high placebo rate eclipses ph. 3 results

MoonLake blamed an unexpectedly high placebo response rate for its much-hyped inflammatory disease prospect missing the key goal of a phase 3 study.
James Waldron Sep 29, 2025 8:05am
Cornucopia overflowing with produce

Odyssey saga continues with $213M series D

Sep 10, 2025 8:00am
Shanghai China at sunrise

Fosun rises again, beaming up 3rd biotech deal in 3 weeks

Aug 29, 2025 10:05am
Graphic image of two hands shaking with employeesexecutives on the forearms of each shaking hand

Sitala seals $670M deal for Fosun immune disease drug

Aug 26, 2025 2:44pm
Goal disorientation and lack of vision

Celldex ends esophageal program despite hitting primary endpoint

Aug 20, 2025 6:42am
Aerial view of karst mountains and sky clouds natural landscape at sunrise in Guilin China

Expedition inks $645M Fosun deal to bring China asset to US

Aug 11, 2025 11:06am